Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Dentsply Sirona is the worldâs largest manufacturer of professional dental produ...
Dentsply Sirona is the worldâs largest manufa...
Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headq...
Spok, Inc., a wholly owned subsidiary of Spok H...
Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company d...
Beyond Air Inc. is a clinical-stage medical dev...
Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company ...
Iterum Therapeutics plc is an Ireland-based cli...
Acorda Therapeutics is a biotechnology company focused on developing therapies tha...
Acorda Therapeutics is a biotechnology company ...
Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and San...
Founded on September 28, 2005 through the merge...
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new...
HOOKIPA Pharma Inc. is a clinical stage biophar...
Join the National Investor Network and get the latest information with your interests in mind.